Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBLG NASDAQ:IINN NASDAQ:INBS NASDAQ:NVNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBLGBone Biologics$2.15$2.62$1.95▼$16.50$3.86M0.656.18 million shs359,053 shsIINNInspira Technologies OXY B.H.N.$1.25+4.2%$1.27$0.40▼$1.65$15.15M2.281.50 million shs342,608 shsINBSIntelligent Bio Solutions$1.76+7.0%$1.67$1.10▼$2.75$14.77M4.59105,431 shs228,919 shsNVNOenVVeno Medical$0.72-5.7%$3.49$0.71▼$5.70$14.60M0.882.17 million shs1.00 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBLGBone Biologics0.00%+1.42%-7.73%-56.21%-68.57%IINNInspira Technologies OXY B.H.N.+4.17%+5.93%+12.11%+56.45%+13.64%INBSIntelligent Bio Solutions+7.32%+10.69%+15.79%-11.11%-1.68%NVNOenVVeno Medical-5.69%-11.76%-84.58%-84.06%-86.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBLGBone Biologics$2.15$2.62$1.95▼$16.50$3.86M0.656.18 million shs359,053 shsIINNInspira Technologies OXY B.H.N.$1.25+4.2%$1.27$0.40▼$1.65$15.15M2.281.50 million shs342,608 shsINBSIntelligent Bio Solutions$1.76+7.0%$1.67$1.10▼$2.75$14.77M4.59105,431 shs228,919 shsNVNOenVVeno Medical$0.72-5.7%$3.49$0.71▼$5.70$14.60M0.882.17 million shs1.00 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBLGBone Biologics0.00%+1.42%-7.73%-56.21%-68.57%IINNInspira Technologies OXY B.H.N.+4.17%+5.93%+12.11%+56.45%+13.64%INBSIntelligent Bio Solutions+7.32%+10.69%+15.79%-11.11%-1.68%NVNOenVVeno Medical-5.69%-11.76%-84.58%-84.06%-86.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBLGBone Biologics 0.00N/AN/AN/AIINNInspira Technologies OXY B.H.N. 3.00Buy$2.0060.00% UpsideINBSIntelligent Bio Solutions 0.00N/AN/AN/ANVNOenVVeno Medical 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest BBLG, NVNO, INBS, and IINN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025NVNOenVVeno MedicalLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBLGBone BiologicsN/AN/AN/AN/A$8.39 per shareN/AIINNInspira Technologies OXY B.H.N.N/AN/AN/AN/A$0.34 per shareN/AINBSIntelligent Bio Solutions$3.05M5.18N/AN/A$0.41 per share4.29NVNOenVVeno MedicalN/AN/AN/AN/A$2.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBLGBone Biologics-$4.11MN/A0.00N/AN/AN/A-100.58%-93.31%11/13/2025 (Estimated)IINNInspira Technologies OXY B.H.N.-$11.05MN/A0.00∞N/AN/AN/AN/AN/AINBSIntelligent Bio Solutions-$10.57M-$2.05N/A5.03N/A-346.22%-231.13%-108.24%11/6/2025 (Estimated)NVNOenVVeno Medical-$21.82M-$1.20N/AN/AN/AN/A-57.35%-53.49%10/29/2025 (Estimated)Latest BBLG, NVNO, INBS, and IINN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025Q4 2025INBSIntelligent Bio Solutions-$0.12-$0.37-$0.25-$0.41$4.30 million$0.84 million8/14/2025Q2 2025BBLGBone Biologics-$0.58-$1.33-$0.75-$1.33N/AN/A7/31/2025Q2 2025NVNOenVVeno Medical-$0.28-$0.33-$0.05-$0.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBLGBone BiologicsN/AN/AN/AN/AN/AIINNInspira Technologies OXY B.H.N.N/AN/AN/AN/AN/AINBSIntelligent Bio SolutionsN/AN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBLGBone BiologicsN/A17.2517.25IINNInspira Technologies OXY B.H.N.0.092.021.89INBSIntelligent Bio SolutionsN/A0.770.65NVNOenVVeno MedicalN/A11.8111.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBLGBone Biologics34.30%IINNInspira Technologies OXY B.H.N.12.72%INBSIntelligent Bio Solutions32.97%NVNOenVVeno Medical34.71%Insider OwnershipCompanyInsider OwnershipBBLGBone Biologics7.50%IINNInspira Technologies OXY B.H.N.29.40%INBSIntelligent Bio Solutions0.28%NVNOenVVeno Medical16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBLGBone Biologics21.80 million1.66 millionNot OptionableIINNInspira Technologies OXY B.H.N.2012.62 million8.91 millionNot OptionableINBSIntelligent Bio Solutions108.98 million8.95 millionNot OptionableNVNOenVVeno Medical3019.25 million16.17 millionOptionableBBLG, NVNO, INBS, and IINN HeadlinesRecent News About These CompaniesenVVeno Medical Shares Plunge 79% on FDA DenialSeptember 1, 2025 | ocbj.comONVNO's Shares Decline on Unfavorable FDA Review Outcome for VenoValveAugust 25, 2025 | zacks.comThis Medical Device Stock Just Plunged A Whopping 71% Today – Do You Own It?August 22, 2025 | msn.comEnVVeno Medical Gets Not-Approvable Letter from FDA for VenoValveAugust 21, 2025 | marketwatch.comFDA denies PMA submission for enVVeno Medical’s VenoValveAugust 20, 2025 | massdevice.comenVVeno tanks after FDA rejects VenoValve approvalAugust 20, 2025 | msn.comenVVeno Medical Corporation: enVVeno Receives Not-Approvable Letter from the FDA for the VenoValveAugust 20, 2025 | finanznachrichten.deenVVeno Medical stock plummets after FDA rejects VenoValve approvalAugust 20, 2025 | au.investing.comenVVeno Medical shares collapse after FDA denies VenoValve approvalAugust 20, 2025 | msn.comenVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)August 20, 2025 | accessnewswire.comAenVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTechAugust 15, 2025 | accessnewswire.comAAltium Capital Management LLC Reduces Stock Position in enVVeno Medical Corporation (NASDAQ:NVNO)August 14, 2025 | marketbeat.comenVVeno Medical (NASDAQ:NVNO) Downgraded to "Sell" Rating by Wall Street ZenAugust 10, 2025 | marketbeat.comHealth Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous InsufficiencyAugust 6, 2025 | accessnewswire.comAenVVeno Medical Participates in a New Virtual Investor “What This Means” Segment to Discuss How President Trump’s Recent CVI Diagnosis May Impact the CompanyAugust 6, 2025 | desmoinesregister.comDenVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the CompanyAugust 4, 2025 | accessnewswire.comAenVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 1, 2025 | accessnewswire.comAenVVeno Medical Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand ConferenceJuly 22, 2025 | indystar.comIenVVeno Medical Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand ConferenceJuly 22, 2025 | accessnewswire.comAEnVVeno Medical Reveals Promising 2-Year Data From VenoValve Clinical TrialJune 7, 2025 | nasdaq.comPositive Interim 2-Year Data from enVVeno Medical’s VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual MeetingJune 7, 2025 | cincinnati.comCNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBBLG, NVNO, INBS, and IINN Company DescriptionsBone Biologics NASDAQ:BBLG$2.15 0.00 (0.00%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$2.07 -0.08 (-3.72%) As of 09:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.Inspira Technologies OXY B.H.N. NASDAQ:IINN$1.25 +0.05 (+4.17%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$1.24 -0.01 (-1.20%) As of 09:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'annana, Israel.Intelligent Bio Solutions NASDAQ:INBS$1.76 +0.12 (+6.99%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$1.73 -0.03 (-1.70%) As of 09:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.enVVeno Medical NASDAQ:NVNO$0.72 -0.04 (-5.69%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$0.72 +0.01 (+1.19%) As of 09:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
